Clarithromycin
- Generic Name
- Clarithromycin
- Brand Names
- Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C38H69NO13
- CAS Number
- 81103-11-9
- Unique Ingredient Identifier
- H1250JIK0A
- Background
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bacteri...
- Indication
An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinu...
- Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
- Associated Therapies
- -
Drug-Drug Interaction Study in Healthy Adult Volunteers
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02275988
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir
- Conditions
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251769
Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 130
- Registration Number
- NCT02248428
- Locations
- 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02188368
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
🇺🇸Wellness Oncology and Hematology, West Hills, California, United States
🇺🇸Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States
Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis After Endoscopic Sinus Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Zheng Liu
- Target Recruit Count
- 187
- Registration Number
- NCT02182492
- Locations
- 🇨🇳
Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 215
- Registration Number
- NCT02175901
- Locations
- 🇨🇳
Shanghai Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, China
Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02171585
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 390
- Registration Number
- NCT02159976
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study of LY2835219 in Participants With Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT02117648
- Locations
- 🇺🇸
Accelerated Comm. Oncology Research Network (ACORN), Memphis, Tennessee, United States
🇺🇸The West Clinic, Memphis, Tennessee, United States
CYP3A4 Activity and Mineral Homeostasis
- Conditions
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 92
- Registration Number
- NCT02019875
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.